Multiple Myeloma Clinical Trials

A listing of Multiple Myeloma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 570 clinical trials
SELIBORDARA: Selinexor Bortezomib and Daratumumab in Multiple Myeloma

Phase 2, single-arm, open, non-randomized, multicenter study of the SINE compound selinexor plus low-dose dexamethasone, in combination with bortezomib and daratumumab. 100 mg selinexor (on days 1, 8, 15 and 22), plus 40 mg dexamethasone (20 mg IV the day of daratumumab and selinexor and 20 mg oral administration the …

neutrophil count
proteasome inhibitor
g-csf
growth factor
serum pregnancy test
  • 16 views
  • 15 Feb, 2021
  • 15 locations
Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma

This study evaluates the safety and efficacy of novel BCMA-targeted CAR-T cell therapy (CBG-002) for patients with relapsed or refractory multiple myeloma (r/r MM). CBG-002 is designed based on

  • 0 views
  • 15 Apr, 2021
  • 1 location
Acupuncture for Chemo-Induced Peripheral Neuropathy in Multiple Myeloma Patients

medication sparing effects in comparison to standard of care management in Multiple Myeloma subjects.

  • 0 views
  • 30 Sep, 2021
  • 1 location
RAPA-201 T Cell Therapy for Relapsed Refractory Multiple Myeloma

RAPA-201-RRMM is an open-label, single-arm, non-randomized multicenter Phase II study of RAPA-201 autologous T cells in adults with relapsed, refractory multiple myeloma who have received at

  • 0 views
  • 19 Jan, 2022
  • 1 location
  • 0 views
  • 14 Jan, 2022
  • 1 location
Pomalidomide Ixazomib and Dexamethasone With or Without Intensification by Cyclophosphamide in Relapsed or Refractory Multiple Myeloma

The study is designed as a multicenter, non-randomized, Phase II trial with one treatment arm. A total of 82 patients of both genders and older than 18 years with relapsed/refractory multiple

neutrophil count
ixazomib
alkylating agents
cyclophosphamide
platelet count
  • 2 views
  • 18 Sep, 2021
  • 18 locations
Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years

The study is designed as a randomized, controlled, open-label, assessor blind, multicenter superiority trial with three parallel groups, and primary endpoint of immunophenotypic complete responses at 18 months after randomization. Block randomization will be performed with a 1:1:1 allocation ratio. Patients will be randomized up front to 3 arms. Patients …

  • 13 views
  • 24 Mar, 2021
  • 89 locations
Daratumumab in Treating Participants With Relapsed Multiple Myeloma After Stem Cell Transplant

This phase II trial studies whether daratumumab and hyaluronidase-fihj and pomalidomide work in treating patients with multiple myeloma that has come back (relapsed) after stem cell transplant

neutrophil count
tumor cells
ejection fraction
growth factor
withdrawn
  • 2 views
  • 03 Jan, 2022
  • 1 location
Study Comparing Continuous Versus Fixed Duration Therapy With Daratumumab Lenalidomide and Dexamethasone for Relapsed Multiple Myeloma

The incorporation of proteasome inhibitors and immunomodulatory drugs into the standard of care has improved the outcome for patients with multiple myeloma (MM) over the past 10 years. However

proteasome inhibitor
dexamethasone
azoospermia
line of therapy
bortezomib
  • 0 views
  • 23 Jan, 2021
  • 1 location
Master Protocol for the Phase 1 Study of Cell Therapies in Multiple Myeloma

Master protocol for cell therapy, Phase 1 proof-of-concept studies., in relapsed and refractory multiple myeloma and includes long-term safety follow-up.

  • 0 views
  • 31 May, 2021
  • 1 location